The Latest Cardiac and Vascular News
Conference Call and Webcast at 8:00 am Eastern Time THE WOODLANDS, Texas, May 05, 2022 (GLOBE NEWSWIRE) — Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX), today reported financial results for the three months ended March 31, 2022 and provided an update on key milestones. “We plan to resubmit our New Drug Application (NDA) for […]
–Completed sale to Sentynl Therapeutics of BridgeBio’s NULIBRY™ (Fosdenopterin) for Injection –Updated strategic collaboration with Helsinn Group to develop, manufacture and commercialize infigratinib in oncology indications in the U.S.; BridgeBio is eligible to receive regulatory and commercial milestone payments as well as tiered royalties on adjusted net sales from Helsinn –Released […]
Conference Call Scheduled for Today, May 4, 2022, at 8:00 a.m. CT (9:00 a.m. ET) Revenues of $56.2 million decreased 4.9% sequentially compared to second quarter this year and decreased 11.1% compared to third quarter last year Fiscal year 22 revenue guidance narrowed to $235 million to $240 million Announced […]
MASON, Ohio–(BUSINESS WIRE)–AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in surgical treatments and therapies for atrial fibrillation (Afib), left atrial appendage (LAA) management and post-operative pain management, today announced first quarter 2022 financial results. “Our team delivered exceptional first quarter performance, with broad-based growth across all key products,” said Michael Carrel, […]
Q1 2022 total revenue was $8.7 million, including product sales of $7.9 million. Core non-COVID-19 product sales were an estimated $7.6 million, and on a constant currency basis were comparable to core product sales a year ago. Product gross margins were 80%. MONMOUTH JUNCTION, N.J., May 3, 2022 /PRNewswire/ — CytoSorbents Corporation (NASDAQ: CTSO), a leader in the […]
On track to achieve 2022 financial guidance Webcast today, May 4, 2022, at 11:30 a.m. Eastern Time CARLSBAD, Calif., May 4, 2022 /PRNewswire/ — Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) today reported financial results for the first quarter of 2022 and recent business achievements. “We are off to a strong start this year highlighted by progress in our […]
ANDOVER, Mass., May 3, 2022 /PRNewswire/ — TransMedics Group, Inc. (“TransMedics”) (Nasdaq: TMDX), a medical technology company that is transforming organ transplant therapy for patients with end-stage lung, heart, and liver failure, today reported financial results for the quarter ended March 31, 2022. Recent Highlights Net revenue of $15.9 million in the first quarter of 2022, […]
ALAMEDA, Calif., May 3, 2022 /PRNewswire/ — Penumbra, Inc. (NYSE: PEN), a global healthcare company focused on innovative therapies, today reported financial results for the first quarter ended March 31, 2022. Revenue of $203.9 million in the first quarter of 2022, an increase of 20.5%, or 21.8% in constant currency1, compared to the first quarter of […]
Initiated Next Phase of European Expansion Strategy with First National Reimbursement in Sweden Market Access Negotiations and Launch Preparations for VAZKEPA Underway Across Multiple European Markets Continued Progress on Go-To-Market Strategy in the US Plans for Regulatory Filings for Approval of VASCEPA® (icosapent ethyl) in Several Additional Countries in 2022 Company to […]
PARIS, May 04, 2022 (GLOBE NEWSWIRE) — Quantum Genomics (Euronext Growth : ALQGC, OTCQX : QNNTF), a biopharmaceutical company specializing in the development of a new drug class directly targeting the brain to treat difficult-to-treat/resistant hypertension and heart failure, announces it is strengthening its leadership team with the appointment of Sarah Merlen-Boulenger as Head […]
